학술논문
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
Document Type
Article
Author
Bazinet, Alexandre; Darbaniyan, Faezeh; Jabbour, Elias; Montalban-Bravo, Guillermo; Ohanian, Maro; Chien, Kelly; Kadia, Tapan; Takahashi, Koichi; Masarova, Lucia; Short, Nicholas; Alvarado, Yesid; Yilmaz, Musa; Ravandi, Farhad; Andreeff, Michael; Kanagal-Shamanna, Rashmi; Ganan-Gomez, Irene; Colla, Simona; Qiao, Wei; Huang, Xuelin; McCue, Deborah; Mirabella, Bailey; Kantarjian, Hagop; Garcia-Manero, Guillermo
Source
In The Lancet Haematology October 2022 9(10):e756-e765
Subject
Language
ISSN
2352-3026